

Technology Advisory Committee A Interests Register

Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]

Publication Date: 27/04/2022

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|------------------|-----------------|-----------------------------|--|----------------|-------------------|-----------------|--|
| Dr Alicia Okines | Clinical expert | Direct & Indirect financial | <p>Dr Okines has received a speaker fee and was compensated for work on an advisory board panel for Seagen, she has also participated in an advisory board for Roche and AstraZeneca and Daiichi Sankyo.</p> <p>Her institution received research funding from Pfizer and Roche, and she received travel support to attend ESMO 2019 from Leo Pharmaceuticals. Received speaker's fees from Pfizer, Lilly and AstraZeneca, and registration for ASCO 2021 and ESMO 2021 was received from Lilly.</p> | N/A | 10.03.2021 | N/A | It was agreed her declarations would not prevent Dr Okines from providing expert advice to the committee |

There were no declarations made at ACM3 on 18 January 2022